Virax Historical Income Statement

VRAX Stock

USD 2.07 0.05 2.48%

Historical analysis of Virax Biolabs income statement accounts such as Tax Provision of 0.0, Depreciation And Amortization of 97.9 K, Interest Expense of 28.3 K or Selling General Administrative of 2.7 M can show how well Virax Biolabs Group performed in making a profits. Evaluating Virax Biolabs income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Virax Biolabs's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Virax Biolabs Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Virax Biolabs Group is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Virax Income Statement Analysis

Virax Biolabs Group Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Virax Biolabs shareholders. The income statement also shows Virax investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Virax Biolabs Income Statement Chart

At this time, Virax Biolabs' Interest Expense is fairly stable compared to the past year. Total Revenue is likely to rise to about 164.2 K in 2024, whereas Net Interest Income is likely to drop (28.2 K) in 2024.

Selling General Administrative Selling And Marketing Expenses Other Operating Expenses Research Development

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Virax Biolabs Group. It is also known as Virax Biolabs overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Virax Biolabs' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Virax Biolabs Group current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
Interest Expense	15.4K	15.5K	26.9K	28.3K
Depreciation And Amortization	1.7M	1.0	103.1K	97.9K

Interest Expense Depreciation And Amortization

Virax Biolabs income statement Correlations

	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Minority Interest
Net Interest Income		0.58	-1.0	0.72	0.76	-0.21	-0.67	0.73	-0.75	-0.73	-0.77	0.65	-0.64	0.15	0.73	-0.73	0.25	-0.73	-0.65	-0.58
Depreciation And Amortization	0.58		-0.58	-0.03	0.28	-0.49	-0.66	0.0	0.0	0.01	-0.02	0.08	0.18	-0.21	0.01	0.01	0.13	0.02	-0.99	0.33
Interest Expense	-1.0	-0.58		-0.72	-0.76	0.21	0.67	-0.73	0.75	0.73	0.77	-0.65	0.64	-0.15	-0.73	0.73	-0.25	0.72	0.65	0.58
Selling General Administrative	0.72	-0.03	-0.72		0.42	-0.11	-0.23	0.98	-0.94	-0.92	-0.92	0.69	-0.91	0.0	0.99	-0.92	0.27	-0.92	-0.06	-0.87
Selling And Marketing Expenses	0.76	0.28	-0.76	0.42		0.22	-0.61	0.45	-0.47	-0.47	-0.54	0.44	-0.47	0.64	0.44	-0.47	0.09	-0.46	-0.36	-0.57
Total Revenue	-0.21	-0.49	0.21	-0.11	0.22		0.62	0.0	-0.12	-0.16	-0.17	0.42	-0.27	0.88	-0.01	-0.16	-0.82	-0.17	0.44	-0.27
Gross Profit	-0.67	-0.66	0.67	-0.23	-0.61	0.62		-0.17	0.09	0.06	0.11	0.13	-0.02	0.17	-0.18	0.06	-0.71	0.04	0.66	0.08
Other Operating Expenses	0.73	0.0	-0.73	0.98	0.45	0.0	-0.17		-0.95	-0.94	-0.94	0.77	-0.92	0.11	1.0	-0.94	0.13	-0.94	-0.1	-0.85
Operating Income	-0.75	0.0	0.75	-0.94	-0.47	-0.12	0.09	-0.95		1.0	1.0	-0.89	0.98	-0.21	-0.95	1.0	0.0	1.0	0.1	0.89
Net Income From Continuing Ops	-0.73	0.01	0.73	-0.92	-0.47	-0.16	0.06	-0.94	1.0		1.0	-0.91	0.98	-0.24	-0.94	1.0	0.05	1.0	0.1	0.88
Ebit	-0.77	-0.02	0.77	-0.92	-0.54	-0.17	0.11	-0.94	1.0	1.0		-0.91	0.98	-0.29	-0.94	1.0	0.04	1.0	0.13	0.89
Research Development	0.65	0.08	-0.65	0.69	0.44	0.42	0.13	0.77	-0.89	-0.91	-0.91		-0.88	0.44	0.77	-0.91	-0.43	-0.91	-0.19	-0.7
Ebitda	-0.64	0.18	0.64	-0.91	-0.47	-0.27	-0.02	-0.92	0.98	0.98	0.98	-0.88		-0.32	-0.92	0.98	0.06	0.98	-0.07	0.94
Cost Of Revenue	0.15	-0.21	-0.15	0.0	0.64	0.88	0.17	0.11	-0.21	-0.24	-0.29	0.44	-0.32		0.09	-0.24	-0.59	-0.24	0.15	-0.38
Total Operating Expenses	0.73	0.01	-0.73	0.99	0.44	-0.01	-0.18	1.0	-0.95	-0.94	-0.94	0.77	-0.92	0.09		-0.94	0.14	-0.94	-0.1	-0.85
Income Before Tax	-0.73	0.01	0.73	-0.92	-0.47	-0.16	0.06	-0.94	1.0	1.0	1.0	-0.91	0.98	-0.24	-0.94		0.05	1.0	0.1	0.88
Total Other Income Expense Net	0.25	0.13	-0.25	0.27	0.09	-0.82	-0.71	0.13	0.0	0.05	0.04	-0.43	0.06	-0.59	0.14	0.05		0.05	-0.1	-0.11
Net Income	-0.73	0.02	0.72	-0.92	-0.46	-0.17	0.04	-0.94	1.0	1.0	1.0	-0.91	0.98	-0.24	-0.94	1.0	0.05		0.08	0.88
Income Tax Expense	-0.65	-0.99	0.65	-0.06	-0.36	0.44	0.66	-0.1	0.1	0.1	0.13	-0.19	-0.07	0.15	-0.1	0.1	-0.1	0.08		-0.23
Minority Interest	-0.58	0.33	0.58	-0.87	-0.57	-0.27	0.08	-0.85	0.89	0.88	0.89	-0.7	0.94	-0.38	-0.85	0.88	-0.11	0.88	-0.23

Click cells to compare fundamentals

Virax Biolabs Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Virax Historical Income Statement

About Virax Income Statement Analysis

Virax Biolabs Income Statement Chart

Other Operating Expenses

Virax Biolabs income statement Correlations

Virax Biolabs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Virax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Tax Provision	Net Interest Income
Depreciation And Amortization	Interest Expense
Selling General Administrative	Selling And Marketing Expenses
Total Revenue	Gross Profit
Other Operating Expenses	Operating Income
Net Income From Continuing Ops	Ebit
Research Development	Ebitda
Cost Of Revenue	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Income Tax Expense	Minority Interest
Reconciled Depreciation

Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebit	+ 1.0	Net Income From Continuing Ops

Interest Expense	- 1.0	Net Interest Income
Income Tax Expense	- 0.99	Depreciation And Amortization
Total Operating Expenses	- 0.95	Operating Income
Operating Income	- 0.95	Other Operating Expenses
Net Income	- 0.94	Total Operating Expenses
Income Before Tax	- 0.94	Total Operating Expenses